Journal article
Bismuth‐Based Quadruple Therapy with Bismuth Subcitrate, Metronidazole, Tetracycline and Omeprazole in the Eradication of Helicobacter pylori
Abstract
BACKGROUND: A previous study showed that 14 days of qid bismuth-based triple therapy with tetracycline 500 mg, metronidazole 250 mg and colloidal bismuth subcitrate 120 mg resulted in excellent Helicobacter pylori eradication rates (89.5%). The present study looked at a shorter treatment period by adding omeprazole and by reducing the dose of tetracycline.
METHODS: One hundred sixty-one patients with H pylori confirmed by histology and …
Authors
Lahaie R; Farley A; Dallaire C; Archambault A; Fallone CA; Ponich T; Hunt R; Oravec M; Whitsitt P; Van Zanten SV
Journal
Canadian Journal of Gastroenterology and Hepatology, Vol. 15, No. 9, pp. 581–585
Publisher
Hindawi
Publication Date
2001
DOI
10.1155/2001/305756
ISSN
2291-2789
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedDose-Response Relationship, DrugDrug Administration ScheduleDrug ResistanceDrug Therapy, CombinationFemaleFollow-Up StudiesHelicobacter InfectionsHelicobacter pyloriHumansMaleMetronidazoleMicrobial Sensitivity TestsMiddle AgedOmeprazoleOrganometallic CompoundsProbabilityTetracyclineTreatment Outcome